Benign prostatic hyperplasia (BPH) is a common proliferative disorder of unknown etiology. We have previously documented that the insulin-like growth factor (IGF) axis is critical for prostate cell growth and is abnormal in BPH. The type 1 IGF receptor (IGF-1R) is constitutively expressed by most body tissues and plays a significant role in regulating cell proliferation, consistent with the role of its ligands (IGF-I and IGF-II) as important mitogenic factors. The Wilms' tumor gene product (WT-1) is a tumor suppressor that has been shown to be altered in rare kidney tumors and is known to regulate IGF-II and IGF-1R. We investigated the possibility that the expression of prostatic WT-1, IGF-1R, and IGF-II genes is altered in patients with BPH. We utilized primary cultures of prostatic stromal cells grown from normal (n ϭ 9) and hyperplastic (n ϭ 9) surgical specimens and analyzed WT-1, IGF-1R, and IGF-II messenger RNA levels. In all of the BPH cell strains, WT-1 expression (measured by RT-PCR and RNase protection assays) was strikingly lower than that found in normal strains (0 -20% of normal, mean 14% of normal, P Ͻ 0.01). The expression of both the IGF-1R (300% of normal, P Ͻ 0.05) and IGF-II (1000% of normal, P Ͻ 0.01) messenger RNAs was higher in BPH strains as compared with normal strains. No changes were seen in stromal cell strains derived from prostatic adenocarcinoma. Thus, in cultured human prostatic stromal cell strains from patients with BPH, decreased WT-1 gene expression is associated with increases in the expression of the IGF-1R and IGF-II genes that are known transcriptional targets of WT-1. These findings indicate that reduced expression of the WT-1 tumor suppressor gene and elevated IGF-1R and IGF-II gene expression may be involved in the pathophysiology of prostatic hyperplasia, implying a new role for the Wilms' tumor gene in nonmalignant states. (J Clin Endocrinol Metab 82: 2198 -2203, 1997 
RNase protection assays) was strikingly lower than that found in normal strains (0 -20% of normal, mean 14% of normal, P Ͻ 0.01). The expression of both the IGF-1R (300% of normal, P Ͻ 0.05) and IGF-II (1000% of normal, P Ͻ 0.01) messenger RNAs was higher in BPH strains as compared with normal strains. No changes were seen in stromal cell strains derived from prostatic adenocarcinoma. Thus, in cultured human prostatic stromal cell strains from patients with BPH, decreased WT-1 gene expression is associated with increases in the expression of the IGF-1R and IGF-II genes that are known transcriptional targets of WT-1. These findings indicate that reduced expression of the WT-1 tumor suppressor gene and elevated IGF-1R and IGF-II gene expression may be involved in the pathophysiology of prostatic hyperplasia, implying a new role for the Wilms' tumor gene in nonmalignant states. (J Clin Endocrinol Metab 82: 2198 -2203, 1997) B ENIGN prostatic hyperplasia (BPH) is the most commonly occurring benign proliferative abnormality found in any internal organ (1) . One in every four men in the United States will require treatment for symptomatic relief of BPH by the time they reach age 80 (2) . The human prostate gland is a composite organ, made up of glandular and nonglandular components and composed of both epithelial and stromal cells (3) . Morphological and histological evaluations of the evolution of the development of BPH have led to the hypothesis that abnormal nodule genesis and growth result from a primarily focal abnormality in the stroma, which acquires the capacity to induce proliferation in adjacent epithelium (4) . The epithelial budding and glandular morphogenesis in BPH are similar to that in embryonic tissue, a process generally forbidden in adult organs, leading to the speculation that BPH may be the result of a reawakening of the embryonic inductive potential of prostatic stroma in adulthood (5) . Recently, it has been proposed that the abnormal stromal-epithelial interaction in BPH may involve the abnormal production of one or several locally produced growth factors (6) .
The insulin-like growth factor (IGF) axis is a multicomponent network of molecules involved in the regulation of cell growth. This axis includes the ligands IGF-I and IGF-II (7), cell-surface receptors, which include the type 1 IGF receptor (IGF-1R) (8) , and a family of high-affinity binding proteins (IGFBPs), which regulate IGF availability to the receptors (9, 10) . The IGFs, their receptors, and their binding proteins participate in endocrine as well as autocrine-paracrine growth processes and may be involved in neoplastic transformation (7) (8) (9) (10) .
The IGF-1R is a membrane-bound tyrosine kinase that mediates the trophic, metabolic, and differentiative effects of the IGFs (11, 12) . Overexpression of IGF-1R in Balb/c 3T3 cells has been shown to abrogate all requirements for exogenous growth factors, suggesting that this receptor plays a central role during the cell cycle (13) . Furthermore, the con-stitutive expression of IGF-1R gene in most tissues is consistent with the putative role of IGFs as critical regulators of cellular growth and differentiation (14) .
The Wilms' tumor gene, WT-1, encodes a zinc-finger DNA-binding protein that has been shown to be deleted or mutated in renal malignancies such as Wilms' tumor (15) . This gene has also been shown to be critical for mesonephric development (16) . The role of WT-1 as a tumor suppressor gene has been demonstrated in Wilms' tumor-derived cell lines in which the WT-1 gene has been shown to be mutated. After transfection with a wild-type WT-1 expression vector, a loss of the malignant phenotype was observed (17) . WT-1 has been shown to repress the expression of a number of genes including Igf2 and Igfr (18, 19) , as well as those encoding other growth factors and receptors (20) . It has been suggested that the loss of negative regulation of the IGF-1R and IGF-II in Wilms' tumor is the primary process that mediates tumor progression (19, 21) .
We have investigated the role of the IGF axis in the prostate by documenting the presence of IGFs and their receptors and IGFBPs and their proteases in seminal plasma (22) (23) (24) and in cultured prostatic cells (25) (26) (27) . We have further shown that prostatic stromal cell strains from BPH patients demonstrate increased IGF-II expression and altered protein and messenger RNA (mRNA) expression of IGFBP-2 and IGFBP-5 (28, 29) . We then proposed that IGF axis abnormalities may be involved in the pathogenesis of BPH (25) (26) (27) (28) (29) .
Hypothesizing that disregulated IGF-1R and IGF-II mRNA expression in the prostates of patients with BPH may be related to altered WT-1 status, we have evaluated WT-1, IGF-1R, and IGF-II gene expression in prostatic cells from such patients and controls.
Methods

Cultures of human prostatic epithelial and stromal cells
Tissue samples were dissected from histologically normal peripheral or central zones, BPH, or adenocarcinomas of specimens obtained by radical prostatectomy, cystoprostatectomy, or suprapubic enucleations from men 55-80 yr old after obtaining informed consent (approved by the Stanford University Institutional Review Board). There was no statistical difference in the mean ages of the three groups studied. None of the patients had received any prior hormonal, radiation, or chemical therapy. Following overnight collagenase digestion of the tissues, epithelial cultures were derived according to previously published protocols (30) . Primary and serial cultures of epithelial cells were maintained in serum-free medium (PFMR-4A supplemented with growth factors) (30) .
Stromal cell strains were established by inoculating collagenase-digested tissues into MCDB 105 (Sigma, St. Louis, MO) supplemented with 10% FBS and gentamicin (100 g/ml) (31). Cells were serially passaged in this same medium. Stromal cell cultures were not labeled by antibodies against keratins or factor VIII, but were stained by antibodies against vimentin and fibronectin.
Cells were grown in serum-free media for 72 h and then used for RNA analysis. Twenty five different stromal strains [9 normal, 9 BPH, 7 derived from prostatic adenocarcinoma (CaP)] and 17 different epithelial strains (7 normal, 5 BPH, 5 CaP) were used for the various analyses. Cells were studied between passage 10 and 15.
RNA analysis
Total RNA was isolated from freshly lysed cells as previously described (24) . RNA samples (1 g) were analyzed by quantitative RT-PCR as previously described (32) . PCR was performed on a Perkin Elmer 4800 thermocycler, and all RT-PCR reagents were purchased from PerkinElmer/Cetus (Norwalk, CT).
After RT, complementary DNA (cDNA) was amplified with the following WT-1 primers: sense, 5Ј-CTG GAA TCA GAT GAA CTT AGG-3Ј and antisense, 5Ј-ACC TGT ATG AGT CCT GGT G-3Ј. These primers amplify a 461-bp double-stranded DNA sequence that flanks exon 5. PCR conditions were 94 C for 1 min, 60 C for 1 min, and 72 C for 1 min for 30 cycles. IGF-II primers were: sense, 5Ј-GGG AAT TCA TTG CTG CTT ACC GCC CCA G-3Ј and antisense, 5Ј-GGA AGC TTA GTA CGT CGT CTC CAC GAG GGC C-3Ј. These primers amplify a 200-bp doublestranded DNA sequence. PCR conditions were as above, except that the denaturing temperature was 93 C instead of 94 C and 25 cycles were used. RNA quantity was normalized for 18S ribosomal RNA (32) that was amplified using the same protocol for 20 cycles after optimization of the assay indicated that to be the ideal linear range for this high abundance ubiquitous mRNA.
The PCR products were electrophoresed on an ethidium bromidestained 2% agarose gel (GIBCO BRL Ultra Pure, Gaithersburg, MD) in TAE buffer. Gels were photographed and analyzed densitometrically on a BioRad 670GS scanning densitometer (Hercules, CA).
For IGF-1R RNA analysis, the same thermocycler and reagents were used, and 33 P-labeled deoxycytidine ATP was purchased from Amersham (Arlington Heights, IL). The primer set for human IGF-1R mRNA was: sense, 5Ј-GGG AAT TCC CCG ACC TCG CTG TGG GG-3Ј and antisense, 5Ј-GGA AGC TTG GAA CAG CAG CAA GTA CTC-3Ј. These primers amplify 255-bp spanning nucleotide positions 64 -310 (33) . PCR conditions for the above primers were 94 C for 1 min, 62 C for 1 min, and 72 C for 1 min for 30 cycles. RNA quantity was normalized for human ribosomal protein 7 (hL7) mRNA (26) , which was amplified by the same protocol but for 15 cycles. The PCR samples were run with [ 33 P deoxycytidine triphosphate (1 million cpm in 100 l reaction mixture), and the reaction products were separated in a precast 10% polyacrylamide TBE minigel (Bio-Rad). Gels were exposed to film overnight and analyzed by densitometry using Molecular Analyst Version 2.0 software (Bio-Rad, Hercules, CA). The sequences of the genes studied by RT-PCR were obtained from Genebank. The primers for PCR were designed by the Macvector software (Oxford Molecular, Oxford, United Kingdom).
Solution-hybridization/RNase protection assay
mRNA identification using 32 P-labeled antisense RNA probes for WT-1, IGF-1R, and cyclophilin were performed on samples as previously described (19, 21) . Briefly, 20-g aliquots of total RNA were hybridized overnight with the probes. After RNase digestion, protected hybrids were resolved on denaturing 6% acrylamide gels, exposed to film, and analyzed by densitometry. To generate a WT-1 antisense RNA probe, a 244-bp BstXI-BamHI fragment corresponding to exon 1 and 2 sequences of a WT-1 cDNA was cloned into pGEM3Z using a singlestranded linker-adapter oligonucleotide. This construct was linearized with HindIII and transcribed with T7 RNA polymerase to produce a 269-base probe, 244 bases of which were complementary to WT-1 mRNA. A human cyclophilin probe template for in vitro transcription was purchased from Ambion (Austin, TX).
Statistical analysis
Experiments were repeated three to five times. Densitometric data were analyzed using standard statistical methods, including Student's t test and ANOVA. Results are reported as mean Ϯ sem.
Results
WT-1 mRNA expression in cultured prostatic cells
We evaluated WT-1 expression in cultured prostatic cells of different histological origins. Total RNA from normal (n ϭ 9) and BPH (n ϭ 9) stromal cell strains was extracted as described above and used for WT-1 mRNA analysis by RT-PCR. When compared with normal stromal cell strains, BPH stromal strains showed a dramatic decrease in WT-1 mRNA expression.
As seen in Fig. 1A , WT-1 mRNA in normal strains ap-peared as a double band representing the two normally occurring alternatively spliced variants of the WT-1 transcript that differ because of the presence or absence of 51 bases within exon 5 (17) . Five normal samples (lanes 7-11) and five BPH samples (lanes 2-6) are shown in respect to the molecular weight markers (x 174/HaeIII ladder and 1-kilobase DNA ladder). Of note, normal strains exhibited some variability in the degree of WT-1 mRNA expression. In comparison, the WT-1 expression in BPH stromal cells was very low or undetectable in all of the nine strains examined. Analysis of the mean of three experiments on 18 strains (9 normal and 9 BPH) are shown in Fig. 1B . After normalization for 18S RNA, stromal strains from BPH exhibited a 7-fold decrease in WT-1 mRNA relative to normal strains (P Ͻ 0.01).
Analysis by solution hybridization/RNase protection assay corroborated this decrease in WT-1 mRNA levels. As shown in the autoradiograph of Fig. 2 , a 240-base protected probe fragment corresponding to the WT-1 mRNA was clearly seen in five normal stromal strains (lanes 2-6), but was essentially undetectable in three BPH strains (lanes 7-9). The identity of the minor band of approximately 60 bases is unknown, but was WT-1 specific and may represent an alternatively spliced minor mRNA form.
Analysis of prostatic epithelial cells revealed no expression of WT-1 mRNA in either normal or hyperplastic strains (Table 1). Analysis of stromal strains derived from prostatic adenocarcinoma disclosed amounts of WT-1 mRNA similar to those detected in normal strains (Table 2) .
IGF-1R mRNA expression in cultured prostatic cells
IGF-1R expression was evaluated from similar prostatic cell strains. Total mRNA from normal and BPH stromal cell strains was extracted as described above and used for IGF-1R mRNA analysis by 33 P-labeled RT-PCR. When compared with normal stromal cell strains, BPH stromal strains showed an increase in IGF-1R mRNA expression.
As seen in Fig. 3A , the RT-PCR product derived from IGF-1R mRNA in normal strains appeared as a single distinct band. Seven normal samples (lanes 2-8) and seven BPH samples (lanes 10 -16) are shown with respect to the molecular weight markers (x 174/HaeIII ladder). Densitometric analysis of these bands was normalized to that of the L7 housekeeping gene for each sample and then plotted.
Analysis of the mean of three experiments on 14 (7 normal and 7 BPH) strains is shown in Fig. 3B . After normalization Mean Ϯ SE of normalized mRNA levels; number of strains tested shown in parentheses. ND, Not detected; NS, not significant (by ANOVA).
FIG. 1. WT-1 expression in prostatic stromal cells.
A, WT-1 mRNA levels were analyzed by RT-PCR and compared with 18S RNA levels. Total RNA (1 g) was reverse transcribed and 18S and WT-1 cDNAs were amplified using 20 and 30 cycles, respectively. Primers amplified 230-and 461-bp fragments, respectively. DNA was electrophoresed on an agarose gel. Five BPH samples (lanes 2-6) and five normal samples (lanes 7-11) are shown in respect to markers (lanes 1, 12) . B, Densitometrically analyzed WT-1 mRNA levels normalized for 18S RNA from nine normal ࡗ and nine BPH ⅜ cell strains; mean Ϯ SEM of each is also shown.
FIG. 2.
Expression of WT-1 in prostatic stromal cells. WT-1 mRNA levels were analyzed by solution hybridization/RNase protection assay with 32 P-labeled antisense RNA probes for WT-1 and cyclophilin (as an internal control). Aliquots (20 g) of total RNA were hybridized overnight at 42 C. After RNase digestion, protected hybrids were resolved on denaturing 6% acrylamide gels and exposed to film. Five normal samples (lanes 2-6) and three BPH samples (lanes 7-9) are shown. Lane 1 contains aliquots of native WT-1 and cyclophilin probes.
for hL7 mRNA, stromal strains from BPH exhibited a 3-fold increase in IGF-1R mRNA relative to normal strains (P Ͻ 0.05). Increased IGF-1R mRNA in prostatic stromal cells from BPH patients was verified using RNase protection assays (data not shown).
Analysis of prostatic epithelial cells disclosed no change in expression of IGF-1R mRNA in hyperplastic strains ( Table 1) . Analysis of stromal strains derived from prostatic adenocarcinoma disclosed amounts of IGF-1R mRNA similar to those detected in normal strains (Table 2) .
IGF II mRNA expression in cultured prostatic cells
Total RNA from normal and BPH stromal cell strains was extracted as described above and used for IGF-II RNA analysis by RT-PCR. When compared with normal stromal cell strains, BPH stromal strains showed a dramatic increase in IGF-II mRNA expression.
As seen in Fig. 4A , the RT-PCR product derived from IGF-II mRNA in normal strains appeared as a single distinct band. Three normal samples (lanes 2-4) and three BPH samples (lanes 5-7) are shown with respect to the molecular weight markers in lanes 1 and 8 (x 174/HaeIII ladder and 1-kilobase DNA ladder). The bands representing the PCR product of IGF-II were dark in the BPH samples and were faint or almost invisible in the normal samples, indicating increased expression of IGF-II mRNA in BPH.
Densitometric analysis of these bands was normalized to that of 18S RNA for each sample and then plotted in a graph. Analysis of the mean of four experiments on 12 strains (6 normal and 6 BPH) are shown in Fig. 4B . After normalization for h18S RNA, stromal strains from BPH exhibited a 10-fold increase in IGF-II mRNA relative to normal strains (P Ͻ 0.01). Analysis of IGF-II expression by Northern blotting analysis disclosed a similar increase in IGF-II expression in hyperplastic strains, as we have previously demonstrated (28) (data not shown).
Analysis of prostatic epithelial cells revealed no expression of IGF-II mRNA in either normal or hyperplastic strains (Table 1) when tested by Northern blotting. Analysis of stromal strains derived from prostatic adenocarcinoma disclosed amounts of IGF-II mRNA similar to those detected in normal strains (Table 2) . 33 P-labeled RT-PCR and compared with L7 mRNA levels. Total RNA (1 g) was reverse transcribed, and L7 and IGF-1R cDNAs were amplified using 20 and 30 cycles, respectively. Primers amplified 157-and 255-bp fragments, respectively. Seven normal samples (lanes 2-8) and seven BPH samples (lanes 10 -16) are shown in respect to markers (lanes 1, 9, and 17) . B, Densitometrically analyzed IGF-1R mRNA levels normalized for L7 RNA from seven normal छ and 7 BPH ⅷ strains is shown; mean Ϯ SEM of each is also shown.
FIG. 4. IGF-II expression in prostatic stromal cells.
A, IGF-II mRNA levels were analyzed by RT-PCR and compared with 18S RNA levels. Total RNA (1 g) was reverse transcribed, and 18S and IGF-II cDNAs were amplified using 20 and 25 cycles, respectively. Primers amplified 140-and 200-bp fragments, respectively. Three normal samples (lanes 2-4) and three BPH samples (lanes 5-7) are shown in respect to markers (lanes 1, 8) . B, Densitometrically analyzed IGF-II mRNA levels normalized for L7 RNA from 6 normal छ and 6 BPH ⅷ strains are shown; Mean Ϯ SEM of each is also shown.
Discussion
The IGF axis is a crucial pathway for stimulating the growth of many cell types. The ontogeny and tissue-specific expression of the various components of the IGF axis are tightly regulated by hormonal, metabolic, and genetic factors (7-10). The human prostate represents a microenvironment in which local expression of IGFs and their receptors has emerged as a potentially critical mechanism for autocrineparacrine growth regulation (22) (23) (24) (25) (26) (27) . In particular, we have demonstrated that the IGF axis is perturbed in the prostates of BPH patients (28, 29) .
The IGF-1R is a transmembrane tyrosine kinase that mediates the trophic, metabolic, and differentiative effects of IGF-I and IGF-II. Beginning at early organogenesis, the IGF-1R gene is constitutively expressed by most body tissues, consistent with the role of the IGF axis in mediating proliferation and differentiation (12) (13) (14) (15) 34) . Several studies have shown that the overexpression of IGF-1R in a fibroblast cell line abrogates all requirements for exogenous growth factors, suggesting that this receptor mediates a central mechanism in cell cycle (13) .
Although relatively little is known about the molecular regulation of the IGF axis in the prostate, it has been shown in other tissues that several transcription factors are known to control the expression of IGFs and the IGF-1R. Among these are SP1, AP1, P53, CEBP (7, 8) , and WT-1 (15, 20) . WT-1 is an inhibitory transcription factor that affects multiple genes, of which the most important may be IGF-II and IGF-1R (15) (16) (17) (18) (19) (20) (21) . WT-1 also suppresses the expression of other growth-regulatory genes, including platelet growth factor-A derived (PDGF-A) (15, 20) , transforming growth factor- §1 (35), colony-stimulating factor-1 (36) , and the retinoic acid receptor (37) .
WT-1 has been previously shown to be involved in mesonephric development and differentiation. In humans, germline mutations of WT-1 are associated with urogenital malformations as well as Wilms' tumors (15, 20) . Transgenic mice homozygous for targeted disruption of WT-1 die in utero and fail to develop kidneys and gonads (16) .
At least in Wilms' tumors, it appears that the increase in the autocrine effects of IGF-II on the IGF-1R is the most critical abnormality that results from decreased WT-1 suppression of gene expression. Supporting this statement is the fact that virtually identical phenotypes may be observed in Wilms' tumors associated with WT-1 mutations and in those associated with IGF-II gene duplication or loss of imprinting of IGF-II (38) .
In this study, we demonstrated that the proliferative disorder BPH is characterized by a decrease in WT-1 mRNA associated with elevated expression of IGF-1R and the IGF-II in prostatic stromal cells. This association is compatible with previous reports demonstrating that WT-1 inhibits transcription of the promoters for the IGF-1R (19, 39) and IGF-II genes (40) . It has also been shown that transfection of WT-1 into Wilms' tumor cells concomitantly suppresses growth as well as IGF-II and IGF-1R expression (21) .
BPH is an extremely common disorder, affecting a large proportion of elderly men (1, 2) . The etiology of this condition remains unknown, but it appears to be related to local factors rather than to systemic hormonal changes. The trophic systems that may influence prostate growth, such as the androgenic and somatotrophic pathways, normally operate at a reduced, rather than increased tone at the age during which BPH develops. Histologically, the changes that occur in the hyperplastic prostate are reminiscent of a regression to a fetal-like state, and include a proliferation of the stroma followed by epithelial growth (3, 4) . To date, no specific molecular defects have been described that could explain these changes. The production of a locally active growth factor that would mediate these phenomena has been proposed (5, 6), and several candidate hormones have been suggested. The loss of WT-1 in the prostatic stroma is compatible with the above hypothesis. Our finding of increased IGF-II and IGF-1R expression in cultured cells could well be related to increased proliferation in vivo.
WT-1 has been implicated in several human diseases other than Wilm's tumor. Testicular cancer has been demonstrated to have decreased expression of WT-1 (15, 20) . On the other hand, the WT-1 gene was found to be overexpressed in several tumor types including leukemia (41) and ovarian cancer (42) , where its mRNA levels appeared to be much higher than in normal tissues. These phenomena may be related to WT-1's ability to enhance transcription of growth factors and other genes when present in a mutated form (17) or in the presence of modulating factors (15) .
A role for WT-1 in prostate disease has not previously been suggested, but our findings indicate that WT-1 may regulate IGF axis homeostasis within the prostatic stroma, and that BPH is associated with a loss of WT-1 and the resulting up-regulation of the IGF-II and the IGF-1R leading to cellular hyperplasia. We have found WT-1 to be reduced in primary cultures from multiple patients, giving further credence to its potential role in the etiology of BPH. It is as yet unclear what mediates the reduction of WT-1 expression in BPH. It may be postulated that its own transcription is regulated by some yet undefined factor that rises with advancing age.
The potential speculative relation between altered WT-1, IGF-1R, and IGF-II expression and hyperplastic prostate growth is shown in a schematic fashion in the theoretical cartoon in Fig. 5 . In normal prostatic stromal cells the levels of WT-1 expression maintain the transcriptional levels of IGF-1R and IGF-II and thereby regulate the rate of stromal cell proliferation. In BPH, repressed transcription of WT-1 in the stromal cells could be associated with increased IGF-1R and IGF-II transcription. This presumably increasingly available IGF-II binds to IGF-1R and initiates its mitogenic effect on prostate stromal cells, thus, theoretically, contributing to the pathogenesis of BPH.
In summary, prostatic stromal cell strains isolated from patients with BPH express reduced amounts of WT-1 mRNA, while overexpressing IGF-II and IGF-1R mRNAs. This set of abnormalities could be involved in an autocrine-paracrine stimulus mediating the abnormal growth of BPH and constitutes the first demonstration of a molecular dysfunction in this common disease.
